Log in

Relevant bibliographies by topics / Percutaneous ablation / Journal articles

To see the other types of publications on this topic, follow the link: Percutaneous ablation.

Journal articles on the topic 'Percutaneous ablation'

Author: Grafiati

Published: 11 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Percutaneous ablation.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Haanschoten, Danielle M., Ahmet Adiyaman, Jaap Jan J. Smit, Peter Paul H. M. Delnoy, Anand R. Ramdat Misier, Fabiano Porta, Robert P. H. Storm van Leeuwen, and Arif Elvan. "Hybrid Ventricular Tachycardia Ablation after Failed Percutaneous Endocardial and Epicardial Ablation." Cardiology 145, no. 2 (November 8, 2019): 88–94. http://dx.doi.org/10.1159/000503251.

Full text

Abstract:

Introduction: Recurrent ventricular tachycardia (VT) after percutaneous ablation is associated with a high morbidity and mortality. We assessed the feasibility of open chest extracorporeal circulation (ECC)-supported 3D multielectrode mapping and targeted VT substrate ablation in patients with previously failed percutaneous endocardial and epicardial VT ablations. Methods: In patients with previously failed percutaneous endocardial and epicardial VT ablations and a high risk of hemodynamic collapse during the procedure, open chest ECC-supported mapping and ablation were performed in a hybrid EP lab setting. Electro-anatomic maps (3D) were acquired during sinus rhythm and VT using a multielectrode mapping catheter (HD grid; Abbott or Pentaray, Biosense Webster). Irrigated radiofrequency ablations of all inducible VT were performed with a contact force ablation catheter. Results: Hybrid VT ablation was performed in 5 patients with structural heart disease (i.e., 3 with previous old myocardial infarction and 2 with nonischemic cardiomyopathy) and recurrent VT. Acute procedural success was achieved in all patients. Four patients were successfully weaned off the ECC. In 1 patient with a severely reduced LVEF (16%), damage to the venous graft occurred after sternotomy and that patient died after 1 month. Four patients (80%) remained VT free after a median follow-up of 6 (IQR 4–10) months. Conclusion: In high-risk patients with previously failed percutaneous endocardial and epicardial VT ablations, open chest ECC-supported multielectrode epicardial mapping revealed a VT substrate in all of the patients, and targeted epicardial ablation abolished VT substrate in these patients.

APA, Harvard, Vancouver, ISO, and other styles

2

Kurup, A., Matthew Callstrom, and Michael Moynagh. "Thermal Ablation of Bone Metastases." Seminars in Interventional Radiology 35, no. 04 (October 2018): 299–308. http://dx.doi.org/10.1055/s-0038-1673422.

Full text

Abstract:

AbstractImage-guided, minimally invasive, percutaneous thermal ablation of bone metastases has unique advantages compared with surgery or radiation therapy. Thermal ablation of osseous metastases may result in significant pain palliation, prevention of skeletal-related events, and durable local tumor control. This article will describe current thermal ablation techniques utilized to treat bone metastases, summarize contemporary evidence supporting such thermal ablation treatments, and outline an approach to percutaneous ablative treatment.

APA, Harvard, Vancouver, ISO, and other styles

3

Hui, Terrence CH, Justin Kwan, and Uei Pua. "Advanced Techniques in the Percutaneous Ablation of Liver Tumours." Diagnostics 11, no. 4 (March 24, 2021): 585. http://dx.doi.org/10.3390/diagnostics11040585.

Full text

Abstract:

Percutaneous ablation is an accepted treatment modality for primary hepatocellular carcinoma (HCC) and liver metastases. The goal of curative ablation is to cause the necrosis of all tumour cells with an adequate margin, akin to surgical resection, while minimising local damage to non-target tissue. Aside from the ablative modality, the proceduralist must decide the most appropriate imaging modality for visualising the tumour and monitoring the ablation zone. The proceduralist may also employ protective measures to minimise injury to non-target organs. This review article discusses the important considerations an interventionalist needs to consider when performing the percutaneous ablation of liver tumours. It covers the different ablative modalities, image guidance, and protective techniques, with an emphasis on new and advanced ablative modalities and adjunctive techniques to optimise results and achieve satisfactory ablation margins.

APA, Harvard, Vancouver, ISO, and other styles

4

Alşalaldeh, Mohammad. "A right atrial arteriovenous hemangioma excision under a beating heart after percutaneous catheter cardiac ablation." Cardiovascular Surgery and Interventions 9, no. 2 (July 7, 2022): 129–31. http://dx.doi.org/10.5606/e-cvsi.2022.1272.

Full text

Abstract:

Percutaneous catheter ablation treatment is an interventional treatment method for atrial fibrillation. Herein, we report the case of a 38-year-old male patient who developed a right atrial mass after two percutaneous catheter ablations. The mass was excised by the beating heart technique, later diagnosed as arteriovenous hemangioma. Arteriovenous hemangioma had not been encountered before as a complication of catheter ablation.

APA, Harvard, Vancouver, ISO, and other styles

5

Dumolard, Lucile, Julien Ghelfi, Gael Roth, Thomas Decaens, and Zuzana Macek Jilkova. "Percutaneous Ablation-Induced Immunomodulation in Hepatocellular Carcinoma." International Journal of Molecular Sciences 21, no. 12 (June 20, 2020): 4398. http://dx.doi.org/10.3390/ijms21124398.

Full text

Abstract:

Hepatocellular carcinoma (HCC) is one of the most common causes of cancer-related deaths worldwide and its incidence is rising. Percutaneous locoregional therapies, such as radiofrequency ablation and microwave ablation, are widely used as curative treatment options for patients with small HCC, but their effectiveness remains restricted because of the associated high rate of recurrence, occurring in about 70% of patients at five years. These thermal ablation techniques have the particularity to induce immunomodulation by destroying tumours, although this is not sufficient to raise an effective antitumour immune response. Ablative therapies combined with immunotherapies could act synergistically to enhance antitumour immunity. This review aims to understand the different immune changes triggered by radiofrequency ablation and microwave ablation as well as the interest in using immunotherapies in combination with thermal ablation techniques as a tool for complementary immunomodulation.

APA, Harvard, Vancouver, ISO, and other styles

6

Gupta, Amit, Besma Musaddaq, Conrad von Stempel, and Shahzad Ilyas. "Percutaneous Renal Ablation." Seminars in Ultrasound, CT and MRI 41, no. 4 (August 2020): 351–56. http://dx.doi.org/10.1053/j.sult.2020.05.004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

He, Xiaofeng, Yueyong Xiao, Xiao Zhang, Peng Du, Xin Zhang, Jie Li, Yunxia An, and Patrick Le Pivert. "Percutaneous Tumor Ablation." Technology in Cancer Research & Treatment 15, no. 4 (July 9, 2016): 597–608. http://dx.doi.org/10.1177/1533034615593855.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Alzubaidi, Sadeer J., Harris Liou, Gia Saini, Nicole Segaran, J. Scott Kriegshauser, Sailendra G. Naidu, Indravadan J. Patel, and Rahmi Oklu. "Percutaneous Image-Guided Ablation of Lung Tumors." Journal of Clinical Medicine 10, no. 24 (December 10, 2021): 5783. http://dx.doi.org/10.3390/jcm10245783.

Full text

Abstract:

Tumors of the lung, including primary cancer and metastases, are notoriously common and difficult to treat. Although surgical resection of lung lesions is often indicated, many conditions disqualify patients from being surgical candidates. Percutaneous image-guided lung ablation is a relatively new set of techniques that offers a promising treatment option for a variety of lung tumors. Although there have been no clinical trials to definitively compare its efficacy to those of traditional treatments, lung ablation is widely practiced and generally accepted to be safe and effective. Especially encouraging results have recently emerged for cryoablation, one of the newer ablative techniques. This article reviews the indications, techniques, contraindications, and complications of percutaneous image-guided ablation of lung tumors with special attention to cryoablation and its recent developments in protocol optimization.

APA, Harvard, Vancouver, ISO, and other styles

9

Salahia, Ghali, Sook Cheng Chin, Ian Zealley, and Richard D. White. "The Role of Interventional Radiology in the Management of Pancreatic Pathologies." Journal of Gastrointestinal and Abdominal Radiology 3, no. 01 (January 2020): 099–113. http://dx.doi.org/10.1055/s-0039-3401335.

Full text

Abstract:

AbstractPancreatic pathologies are varied and wide-ranging, and a multidisciplinary approach is essential for effective diagnosis and management. We describe image-guided percutaneous (nonendoscopic) interventions in the management of pancreatic disease, with emphasis on inflammatory and neoplastic pancreatic pathologies and on the transplanted pancreas. Image-guided treatments for the complications of pancreatitis include percutaneous interventions on simple and complex peripancreatic collections, pseudocysts, and fistulas. Vascular interventions predominantly focus on the treatment of pseudoaneurysms, hemorrhagic pseudocysts, and arteriovenous malformations. Emerging ablative techniques for pancreatic cancer are promising and include percutaneous radiofrequency ablation, microwave ablation, irreversible electroporation, and electrochemotherapy. Image-guided interventions on the transplanted pancreas commonly include percutaneous biopsy and drainage in addition to endovascular treatments of vascular complications.

APA, Harvard, Vancouver, ISO, and other styles

10

Nimsdorf, F., C. Happel, H. Ackermann, F. Grünwald, and H. Korkusuz. "Percutaneous microwave ablation of benign thyroid nodules." Nuklearmedizin 54, no. 01 (2015): 13–19. http://dx.doi.org/10.3413/nukmed-0678-14-06.

Full text

Abstract:

SummaryAim: Thyroid nodules represent a common clinical issue. Amongst other minimally invasive procedures, percutaneous microwave ablation (MWA) poses a promising new approach. The goal of this retrospective study is to find out if there is a correlation between volume reduction after 3 months and 99mTcuptake reduction of treated thyroid nodules. Patients, methods: 14 patients with 18 nodules were treated with MWA. Pre-ablative assessment included sonographical and functional imaging of the thyroid with 99mTcpertechnetate and 99mTc-MIBI. Additionally, patients underwent thyroid scintigraphy 24 hours after ablation in order to evaluate the impact of the treatment on a functional level and to ensure sufficient ablation of the targeted area. At a 3-month follow-up, ultrasound examination was performed to assess nodular volume reduction. Results: Mean relative nodular volume reduction after three months was 55.4 ± 17.9% (p < 0.05). 99mTcuptake 24 hours after treatment was 45.2 ± 31.9% (99mTc-MIBI) and 35.7 ± 20.3% (99mTcpertechnetate) lower than prior to ablation (p < 0.05). Correlating reduction of volume and 99mTc-uptake, Pearson's r was 0.41 (p < 0.05) for nodules imaged with 99mTc-MIBI and –0.98 (p < 0.05) for 99mTc-pertechnetate. According to scintigraphy 99.6 ± 22.6% of the determined target area could be successfully ablated. Conclusions: MWA can be considered as an efficient, low-risk and convenient new approach to the treatment of benign thyroid nodules. Furthermore, scintigraphy seems to serve as a potential prognostic tool for the later morphological outcome, allowing rapid evaluation of the targeted area in post-ablative examination.

APA, Harvard, Vancouver, ISO, and other styles

11

Bréhier, Germain, Louis Besnier, Anaïs Delagnes, Frédéric Oberti, Jérôme Lebigot, Christophe Aubé, and Anita Paisant. "Imaging after percutaneous thermal and non-thermal ablation of hepatic tumour: normal appearances, progression and complications." British Journal of Radiology 94, no. 1123 (July 1, 2021): 20201327. http://dx.doi.org/10.1259/bjr.20201327.

Full text

Abstract:

The increasing number of liver tumours treated by percutaneous ablation leads all radiologists to be confronted with the difficult interpretation of post-ablation imaging. Radiofrequency and microwave techniques are most commonly used. Recently, irreversible electroporation treatments that do not induce coagulation necrosis but cellular apoptose and respect the collagen architecture of bile ducts and vessels have been introduced and lead to specific post-ablation features and evolution. Ablations cause ‘normal’ changes in ablation and periablation zones. It is necessary to know these post-ablation features to avoid the misinterpretation of recurrence or complication that would lead to unnecessary treatments. Another challenge for the radiologist is to detect as early as possible the residual unablated tumour or the disease progression (local progression and tumour seeding) that will require a new treatment. Finally, the complications, frequent or rarer, should be recognised to be managed adequately. The purpose of this article is therefore to describe the large spectrum of normal and pathological aspects related to the treatment of hepatic tumour by percutaneous thermal ablation and irreversible electroporation ablation.

APA, Harvard, Vancouver, ISO, and other styles

12

Hui, Terrence Chi Hong, Ming Yann Lim, Amit Anand Karandikar, Siu Cheng Loke, and Uei Pua. "A Technical Guide to Palliative Ablation of Recurrent Cancers in the Deep Spaces of the Suprahyoid Neck." Seminars in Interventional Radiology 39, no. 02 (April 2022): 184–91. http://dx.doi.org/10.1055/s-0042-1745764.

Full text

Abstract:

AbstractTreatment options for patients with recurrent head and neck cancer, whether locoregional recurrence of previously treated head and neck cancer or secondary primary malignancy, are limited. Percutaneous ablation is a minimally invasive procedure that can be used with palliative intent in the head and neck to achieve symptomatic relief and local tumor control, potentially fulfilling treatment gaps of current standard of care options. Image guidance is key when navigating the deep spaces of the neck with special attention paid to critical structures within the carotid sheath. This review article provides an overview and highlights the important nuances of performing percutaneous ablations in the head and neck. It covers general principles, ablative modalities, image guidance, procedural technique, expected outcomes, and possible complications.

APA, Harvard, Vancouver, ISO, and other styles

13

Camacho, Juan C., Elena N. Petre, and Constantinos T. Sofocleous. "Thermal Ablation of Metastatic Colon Cancer to the Liver." Seminars in Interventional Radiology 36, no. 04 (October 2019): 310–18. http://dx.doi.org/10.1055/s-0039-1698754.

Full text

Abstract:

AbstractColorectal cancer (CRC) is responsible for approximately 10% of cancer-related deaths in the Western world. Liver metastases are frequently seen at the time of diagnosis and throughout the course of the disease. Surgical resection is often considered as it provides long-term survival; however, few patients are candidates for resection. Percutaneous ablative therapies are also used in the management of this patient population. Different thermal ablation (TA) technologies are available including radiofrequency ablation, microwave ablation (MWA), laser, and cryoablation. There is growing evidence about the role of interventional oncology and image-guided percutaneous ablation in the management of metastatic colorectal liver disease. This article aims to outline the technical considerations, outcomes, and rational of TA in the management of patients with CRC liver metastases, focusing on the emerging role of MWA.

APA, Harvard, Vancouver, ISO, and other styles

14

Shapiro, Robert S. "Cryotherapy and Percutaneous Ablation." American Journal of Roentgenology 182, no. 6 (June 2004): 1597. http://dx.doi.org/10.2214/ajr.182.6.1821597a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Robert Sheu, Yun, and Kelvin Hong. "Percutaneous Lung Tumor Ablation." Techniques in Vascular and Interventional Radiology 16, no. 4 (December 2013): 239–52. http://dx.doi.org/10.1053/j.tvir.2013.09.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Miller, Mickey. "Percutaneous ablation of gallstones." Annals of Emergency Medicine 20, no. 7 (July 1991): 826. http://dx.doi.org/10.1016/s0196-0644(05)80866-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Saksena, Mansi, and D. Gervais. "Percutaneous renal tumor ablation." Abdominal Imaging 34, no. 5 (December 17, 2008): 582–87. http://dx.doi.org/10.1007/s00261-008-9478-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Filippiadis, Dimitrios K., Sean Tutton, and Alexis Kelekis. "Percutaneous bone lesion ablation." La radiologia medica 119, no. 7 (June 4, 2014): 462–69. http://dx.doi.org/10.1007/s11547-014-0418-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Dempsey, Daniel T., Catherine Contreras, Richard Milner, Cyril Abrahams, and John V. White. "Percutaneous ablation of gallstones." Journal of Surgical Research 49, no. 2 (August 1990): 116–20. http://dx.doi.org/10.1016/0022-4804(90)90248-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Folch, Erik, Yanglin Guo, and Michal Senitko. "Therapeutic Bronchoscopy for Lung Nodules: Where Are We Now?" Seminars in Respiratory and Critical Care Medicine 43, no. 04 (August 2022): 480–91. http://dx.doi.org/10.1055/s-0042-1749368.

Full text

Abstract:

AbstractLobar resection has been the established standard of care for peripheral early-stage non—small cell lung cancer (NSCLC). Over the last few years, surgical lung sparing approach (sublobar resection [SLR]) has been compared with lobar resection in T1N0 NSCLC. Three nonsurgical options are available in those patients who have a prohibitive surgical risk, and those who refuse surgery: stereotactic body radiotherapy (SBRT), percutaneous ablation, and bronchoscopic ablation. Local ablation involves placement of a probe into a tumor, and subsequent application of either heat or cold energy, pulsing electrical fields, or placement of radioactive source under an image guidance to create a zone of cell death that encompasses the targeted lesion and an ablation margin. Despite being in their infancy, the bronchoscopic ablative techniques are undergoing rapid research, as they extrapolate a significant knowledge-base from the percutaneous techniques that have been in the radiologist's armamentarium since 2000. Here, we discuss selected endoscopic and percutaneous thermal and non-thermal therapies with the focus on their efficacy and safety.

APA, Harvard, Vancouver, ISO, and other styles

21

Sparchez, Zeno, Tudor Mocan, Nadim All Hajjar, Adrian Bartos, Claudia Hagiu, Daniela Matei, Rares Craciun, Lavinia Patricia Mocan, Mihaela Sparchez, and Daniel Corneliu Leucuta. "Percutaneous ultrasound guided radiofrequency and microwave ablation in the treatment of hepatic metastases. A monocentric initial experience." Medical Ultrasonography 21, no. 3 (August 31, 2019): 217. http://dx.doi.org/10.11152/mu-1957.

Full text

Abstract:

Aim: Percutaneous radiofrequency (RFA) and microwave ablation (MWA) are currently the best treatment options forpatients with liver metastases (LM) who cannot undergo a liver resection procedure. Presently, few studies have evaluated theefficacy of tumor ablation in beginner’s hands but none at all in hepatic metastasis. Our aim was to report the initial experiencewith ultrasound as a tool to guide tumor ablation in a low volume center with no experience in tumor ablation.Material and methods: We conducted a retrospective cohort study, on a series of 61 patients who had undergone percutaneous US-guided ablations for 82 LM between 2010 and 2015. Long term outcome predictors were assessed using univariate and multivariate analysis.Results: Complete ablation was achieved in 86.9% of cases (53/61). All MWA sessions (20/20) attained ablation margins >5mm, compared to 79% (49/62) for RFA sessions (p=0.031). Ablation time was significantly shorter for MWA, with a median duration of 10 minutes (range: 6-12) vs. 14 minutes (range: 10-19.5, p=0.003). There was no statistically significant difference in local tumor progression (LTP)-free survival rates between MWA and RFA (p=0.154). On univariate analysis, significant predictors for local recurrence were multiple metastases (p=0.013) and ablation margins <5 mm (p<.001), both retaining significance on multivariate analysis. Significant predictors for distant recurrence on both univariate and multivariate analysis were multiple metastases (p<0.001) and non-colorectal cancer metastases (p<0.05).Conclusion: A larger than 5 mm ablation size is critical for local tumor control. We favor the use of MWA due to its ability to achieve ablation in significantlyshorter times with less incomplete ablations.

APA, Harvard, Vancouver, ISO, and other styles

22

Maria, Tsitskari, and Christos Georgiades. "Percutaneous Cryoablation for Renal Cell Carcinoma." Journal of Kidney Cancer and VHL 2, no. 3 (June 9, 2015): 105–13. http://dx.doi.org/10.15586/jkcvhl.2015.34.

Full text

Abstract:

Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults. Nephron sparing resection (partial nephrectomy) has been the “gold standard” for the treatment of resectable disease. With the widespread use of cross sectional imaging techniques, more cases of renal cell cancers are detected at an early stage, i.e. stage 1A or 1B. This has provided an impetus for expanding the nephron sparing options and especially, percutaneous ablative techniques. Percutaneous ablation for RCC is now performed as a standard therapeutic nephron-sparing option in patients who are poor candidates for resection or when there is a need to preserve renal function due to comorbid conditions, multiple renal cell carcinomas, and/or heritable renal cancer syndromes. During the last few years, percutaneous cryoablation has been gaining acceptance as a curative treatment option for small renal cancers. Clinical studies to date indicate that cryoablation is a safe and effective therapeutic method with acceptable short and long term outcomes and with a low risk, in the appropriate setting. In addition it seems to offer some advantages over radio frequency ablation (RFA) and other thermal ablation techniques for renal masses.

APA, Harvard, Vancouver, ISO, and other styles

23

Puijk, Robbert S., Alette H. Ruarus, Hester J. Scheffer, Laurien G. P. H. Vroomen, Aukje A. J. M. van Tilborg, Jan J. J. de Vries, Ferco H. Berger, Petrousjka M. P. van den Tol, and Martijn R. Meijerink. "Percutaneous Liver Tumour Ablation: Image Guidance, Endpoint Assessment, and Quality Control." Canadian Association of Radiologists Journal 69, no. 1 (February 2018): 51–62. http://dx.doi.org/10.1016/j.carj.2017.11.001.

Full text

Abstract:

Liver tumour ablation nowadays represents a routine treatment option for patients with primary and secondary liver tumours. Radiofrequency ablation and microwave ablation are the most widely adopted methods, although novel techniques, such as irreversible electroporation, are quickly working their way up. The percutaneous approach is rapidly gaining popularity because of its minimally invasive character, low complication rate, good efficacy rate, and repeatability. However, matched to partial hepatectomy and open ablations, the issue of ablation site recurrences remains unresolved and necessitates further improvement. For percutaneous liver tumour ablation, several real-time imaging modalities are available to improve tumour visibility, detect surrounding critical structures, guide applicators, monitor treatment effect, and, if necessary, adapt or repeat energy delivery. Known predictors for success are tumour size, location, lesion conspicuity, tumour-free margin, and operator experience. The implementation of reliable endpoints to assess treatment efficacy allows for completion-procedures, either within the same session or within a couple of weeks after the procedure. Although the effect on overall survival may be trivial, (local) progression-free survival will indisputably improve with the implementation of reliable endpoints. This article reviews the available needle navigation techniques, evaluates potential treatment endpoints, and proposes an algorithm for quality control after the procedure.

APA, Harvard, Vancouver, ISO, and other styles

24

Gunn, Andrew J., Benjamin J. Mullenbach, May M. Poundstone, Jennifer B. Gordetsky, Edgar S. Underwood, and Soroush Rais-Bahrami. "Trans-Arterial Embolization of Renal Cell Carcinoma prior to Percutaneous Ablation: Technical Aspects, Institutional Experience, and Brief Review of the Literature." Current Urology 12, no. 1 (2018): 43–49. http://dx.doi.org/10.1159/000447230.

Full text

Abstract:

This report describes the technical aspects of trans-arterial embolization (TAE) of renal cell carcinoma prior to percutaneous ablation. All patients (n = 11) had a single renal mass (mean tumor diameter = 50.2 mm; range: 28-84 mm). Selective TAE was performed via the common femoral artery. Embolic materials included: particles alone (n = 4), coils alone (n = 1), particles + ethiodized oil (n = 2), particles + coils (n = 1), ethiodized oil + ethanol (n = 2), and particles + ethanol (n = 1). All embolizations were technically successful and no complications have been reported. After embolization, 10 patients underwent cryoablation while 1 patient underwent microwave ablation. Ablations were technically successful in 10 of the 11 patients. Only 3 minor complications were identified but none required treatment. No adverse effect on the patient's glomerular filtration rate was seen from the additional procedure (p = 0.84). TAE of renal cell carcinoma prior to percutaneous ablation is safe and technically-feasible.

APA, Harvard, Vancouver, ISO, and other styles

25

Mahnken, Andreas, Alexander König, and Jens Figiel. "Current Technique and Application of Percutaneous Cryotherapy." RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren 190, no. 09 (April 17, 2018): 836–46. http://dx.doi.org/10.1055/a-0598-5134.

Full text

Abstract:

Purpose Local ablative therapies have become an established treatment option in interventional oncology. Radiofrequency ablation (RFA) and microwave ablation (MWA) are a standard of care in the treatment of hepatocellular carcinoma (HCC). Currently, there is an increasing interest in cryotherapy, one of the oldest ablation techniques. It has some unique characteristics with regard to technology and mechanism of action. Materials and Methods A systematic literature search using the terms cryotherapy, cryosurgery and cryoablation was performed. Selected studies are presented dealing with the mechanism of action, cryobiology and clinical use of percutaneous, image-guided cryoablation. Recent developments and perspectives are presented. Results Cryotherapy is increasingly used and has been included in guidelines for selected tumor entities such as renal cell carcinoma. Cryo-immunotherapy and combination treatments are future areas of interest. Conclusion Cryoabalation may be used in many indications. Its major advantages are its unique visualization and the anesthesiologic effects of cold. While there are only a few prospectively randomized trials, the existing data on the use of cryoablation is promising. Its use appears to be justified in selected tumors, oligometastatic patients and for palliative indications. Key Points Citation Format

APA, Harvard, Vancouver, ISO, and other styles

26

Wai, Ophelia Ka Heng, Lawrence Fung Him Ng, Peter San Ming Yu, and James Chi Sang Chan. "Post biopsy Liver Hemorrhage Successfully Controlled by Ultrasound-guided Percutaneous Microwave Ablation." Journal of Clinical Imaging Science 6 (September 19, 2016): 34. http://dx.doi.org/10.4103/2156-7514.190859.

Full text

Abstract:

Percutaneous microwave coagulation therapy has been one of the major new developments in tumor ablation. Microwave ablation has also been used intraoperatively to achieve hemostasis at surgical margins in laparotomy. However, the use of microwave ablation for coagulation and hemostasis through percutaneous approach has not been described in the literature. Here, we report a case of hepatic amyloidosis with massive post biopsy liver hemorrhage, which could not be by transarterial embolization, and subsequently controlled by ultrasound-guided percutaneous microwave ablation. To the best of our knowledge, this is the first reported case of this technology application in human.

APA, Harvard, Vancouver, ISO, and other styles

27

D’Onofrio, Mirko, Valentina Ciaravino, Riccardo De Robertis, Emilio Barbi, Roberto Salvia, Roberto Girelli, Salvatore Paiella, Camilla Gasparini, Nicolò Cardobi, and Claudio Bassi. "Percutaneous ablation of pancreatic cancer." World Journal of Gastroenterology 22, no. 44 (2016): 9661. http://dx.doi.org/10.3748/wjg.v22.i44.9661.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Neeman, Ziv, Jay W. Patti, and Bradford J. Wood. "Percutaneous Radiofrequency Ablation of Chordoma." American Journal of Roentgenology 179, no. 5 (November 2002): 1330–32. http://dx.doi.org/10.2214/ajr.179.5.1791330.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Albisinni, Ugo, Eugenio Rimondi, Maria Cristina Malaguti, and Rosanna Ciminari. "Percutaneous Radiofrequency Ablation of Chordoma." American Journal of Roentgenology 183, no. 1 (July 2004): 245–46. http://dx.doi.org/10.2214/ajr.183.1.1830245.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Weinstein, Jeffrey L., and Muneeb Ahmed. "Percutaneous Ablation for Hepatocellular Carcinoma." American Journal of Roentgenology 210, no. 6 (June 2018): 1368–75. http://dx.doi.org/10.2214/ajr.17.18695.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Gelczer, R. K., J. W. Charboneau, S. Hussain, and D. L. Brown. "Complications of percutaneous ethanol ablation." Journal of Ultrasound in Medicine 17, no. 8 (August 1998): 531–33. http://dx.doi.org/10.7863/jum.1998.17.8.531.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Dalal, Paras. "Percutaneous Ablation for Lung Tumors." Clinical Pulmonary Medicine 20, no. 2 (March 2013): 97–107. http://dx.doi.org/10.1097/cpm.0b013e318285b936.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Venkatesan, Aradhana M., Julia Locklin, Damian E. Dupuy, and Bradford J. Wood. "Percutaneous Ablation of Adrenal Tumors." Techniques in Vascular and Interventional Radiology 13, no. 2 (June 2010): 89–99. http://dx.doi.org/10.1053/j.tvir.2010.02.004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Brennan, Ian M., Salomao Faintuch, and Muneeb Ahmed. "Preparation for Percutaneous Ablation Procedures." Techniques in Vascular and Interventional Radiology 16, no. 4 (December 2013): 209–18. http://dx.doi.org/10.1053/j.tvir.2013.08.004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Gervais, Debra. "Percutaneous Ablation of Renal Malignancies." Journal of Vascular and Interventional Radiology 16, no. 2 (February 2005): P210—P212. http://dx.doi.org/10.1016/s1051-0443(05)70170-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Venkatesan, Aradhana M., Bradford J. Wood, and Debra A. Gervais. "Percutaneous Ablation in the Kidney." Radiology 261, no. 2 (November 2011): 375–91. http://dx.doi.org/10.1148/radiol.11091207.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Bansal, Devanshu, and Rajeev Kumar. "Percutaneous ablation for renal masses." Annals of Translational Medicine 7, S6 (September 2019): S174. http://dx.doi.org/10.21037/atm.2019.07.96.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

McCarley, James, and Michael Soulen. "Percutaneous Ablation of Hepatic Tumors." Seminars in Interventional Radiology 27, no. 03 (August 20, 2010): 255–60. http://dx.doi.org/10.1055/s-0030-1261783.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Seggewiss, Hubert. "Percutaneous alcohol ablation in HOCM." Catheterization and Cardiovascular Interventions 48, no. 2 (October 1999): 241b—242a. http://dx.doi.org/10.1002/(sici)1522-726x(199910)48:2<241b::aid-ccd33>3.0.co;2-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Rubin, David N., E. Murat Tuzcu, and Harry M. Lever. "Percutaneous transluminal septal myocardial ablation." Current Cardiology Reports 2, no. 2 (March 2000): 160–65. http://dx.doi.org/10.1007/s11886-000-0014-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Thakore, Sanket, and Juan Carlos Perez Lozada. "Percutaneous Ablation of Intrathoracic Malignancy." Current Pulmonology Reports 9, no. 4 (October 21, 2020): 171–80. http://dx.doi.org/10.1007/s13665-020-00262-y.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Tranberg, K. G. "Percutaneous ablation of liver tumours." Best Practice & Research Clinical Gastroenterology 18, no. 1 (February 2004): 125–45. http://dx.doi.org/10.1016/j.bpg.2003.08.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Deschamps, F., G. Farouil, and T. de Baere. "Percutaneous ablation of bone tumors." Diagnostic and Interventional Imaging 95, no. 7-8 (July 2014): 659–63. http://dx.doi.org/10.1016/j.diii.2014.04.004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Ioannou, George N. "Percutaneous ablation for hepatocellular carcinoma." Hepatology 41, no. 4 (2005): 942. http://dx.doi.org/10.1002/hep.20641.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Wood, Bradford J., Jeffrey R. Ramkaransingh, Tito Fojo, McClellan M. Walther, and Stephen K. Libutti. "Percutaneous tumor ablation with radiofrequency." Cancer 94, no. 2 (January 15, 2002): 443–51. http://dx.doi.org/10.1002/cncr.10234.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Mansur, Arian, Tushar Garg, Apurva Shrigiriwar, Vahid Etezadi, Christos Georgiades, Peiman Habibollahi, Timothy C. Huber, et al. "Image-Guided Percutaneous Ablation for Primary and Metastatic Tumors." Diagnostics 12, no. 6 (May 24, 2022): 1300. http://dx.doi.org/10.3390/diagnostics12061300.

Full text

Abstract:

Image-guided percutaneous ablation methods have been further developed during the recent two decades and have transformed the minimally invasive and precision features of treatment options targeting primary and metastatic tumors. They work by percutaneously introducing applicators to precisely destroy a tumor and offer much lower risks than conventional methods. There are usually shorter recovery periods, less bleeding, and more preservation of organ parenchyma, expanding the treatment options of patients with cancer who may not be eligible for resection. Image-guided ablation techniques are currently utilized for the treatment of primary and metastatic tumors in various organs including the liver, pancreas, kidneys, thyroid and parathyroid, prostate, lung, bone, and soft tissue. This article provides a brief review of the various imaging modalities and available ablation techniques and discusses their applications and associated complications in various organs.

APA, Harvard, Vancouver, ISO, and other styles

47

Galambos, David Maxwell, Aliaksei Salei, Soroush Rais-Bahrami, and Rakesh K. Varma. "Intrahepatic renal cell carcinoma implantation along a percutaneous biopsy and cryoablation probe tract." BMJ Case Reports 15, no. 5 (May 2022): e248250. http://dx.doi.org/10.1136/bcr-2021-248250.

Full text

Abstract:

A man in his 60s underwent percutaneous biopsy and cryoablation of a right upper pole clear cell renal cell carcinoma followed by repeat cryoablation 8 months later for possible residual disease. The patient was followed with imaging with documented stability for 19 months after repeat ablation. However, imaging at 32 months demonstrated intrahepatic nodular enhancing lesions along the initial percutaneous biopsy and ablation tract, consistent with metastatic implantation. The patient underwent repeat percutaneous biopsy and two rounds of microwave ablation for treatment of the intrahepatic implants, with no residual disease at 10 months postablation. While needle tract seeding is a known complication of percutaneous manipulation of various abdominopelvic malignancies, there have been no prior reports of intrahepatic metastatic implants related to percutaneous renal cell carcinoma ablation. Awareness of this potential complication is important for treatment planning, informed consent and surveillance. This report shares our experience of the management of intrahepatic metastatic implants.

APA, Harvard, Vancouver, ISO, and other styles

48

Tulaka, Budi, Bradley Jimmy Waleleng, and Luciana Rotty. "Purcutaneus Radiofrequency Ablation In Liver Tumor." Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy 23, no. 2 (September 6, 2022): 237–43. http://dx.doi.org/10.24871/2322022237-243.

Full text

Abstract:

Tumor ablation is a minimally invasive approach commonly used in the treatment of liver tumors. Over the last two decades, percutaneous radiofrequency ablation (RFA) has been widely used for primary tumors and small metastases, especially in the liver. Effective treatment of RFA can be accomplished by complete ablation of the tumor accompanied by a margin resection of at least 0.5 cm. One of the commonly used methods is percutaneous radiofrequency ablation. The overall and disease-free survival rate of RFA was found to be more effective than that observed with surgical resection. The success rate of RFA is highly dependent on the precision of tumor targeting, which is influenced by two main factors, such as electrode tip placement and angulation for electrode placement. In this literature review, we will discuss about percutaneous radiofrequency ablation.

APA, Harvard, Vancouver, ISO, and other styles

49

Arif, Kamil, and Andrew J. Gunn. "Pneumodissection during Percutaneous Renal Ablation Resulting in Air Embolism: Percutaneous Management and a Review of the Literature." Seminars in Interventional Radiology 36, no. 02 (May 22, 2019): 120–25. http://dx.doi.org/10.1055/s-0039-1688426.

Full text

Abstract:

AbstractPercutaneous renal ablation is a nephron-sparing approach for selected patients with renal cell carcinoma. Common complications include hemorrhage, injury to the urinary collecting system, and abscess formation. The purpose of this article is to present a case of vascular air embolism as a complication of pneumodissection performed during percutaneous ablation of renal cell carcinoma, discuss its successful percutaneous management, review common complications of renal ablation, and outline steps physicians can take to lessen these complications.

APA, Harvard, Vancouver, ISO, and other styles

50

Wimmer, Thomas, Govindarajan Srimathveeravalli, Mikhail Silk, Sebastien Monette, Narendra Gutta, Majid Maybody, Joseph P. Erinjery, Jonathan A. Coleman, Stephen B. Solomon, and Constantinos T. Sofocleous. "Feasibility of a Modified Biopsy Needle for Irreversible Electroporation Ablation and Periprocedural Tissue Sampling." Technology in Cancer Research & Treatment 15, no. 6 (July 9, 2016): 749–58. http://dx.doi.org/10.1177/1533034615608739.

Full text

Abstract:

Objectives: To test the feasibility of modified biopsy needles as probes for irreversible electroporation ablation and periprocedural biopsy. Methods: Core biopsy needles of 16-G/9-cm were customized to serve as experimental ablation probes. Computed tomography-guided percutaneous irreversible electroporation was performed in in vivo porcine kidneys with pairs of experimental (n = 10) or standard probes (n = 10) using a single parameter set (1667 V/cm, ninety 100 µs pulses). Two biopsy samples were taken immediately following ablation using the experimental probes (n = 20). Ablation outcomes were compared using computed tomography, simulation, and histology. Biopsy and necropsy histology were compared. Results: Simulation-suggested ablations with experimental probes were smaller than that with standard electrodes (455.23 vs 543.16 mm2), although both exhibited similar shape. Computed tomography (standard: 556 ± 61 mm2, experimental: 515 ± 67 mm2; P = .25) and histology (standard: 313 ± 77 mm2, experimental: 275 ± 75 mm2; P = .29) indicated ablations with experimental probes were not significantly different from the standard. Histopathology indicated similar morphological changes in both groups. Biopsies from the ablation zone yielded at least 1 core with sufficient tissue for analysis (11 of the 20). Conclusions: A combined probe for irreversible electroporation ablation and periprocedural tissue sampling from the ablation zone is feasible. Ablation outcomes are comparable to those of standard electrodes.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!